Oxford Brain Diagnostics Ltd. is pioneering a novel approach to brain health assessment through its proprietary technology known as Cortical Disarray Measurement (CDM®). This innovative method focuses on analyzing the cellular structure of the brain, particularly the quality of grey matter, to provide insights that are critical for the diagnosis and management of neurodegenerative conditions such as Alzheimer’s disease. By utilizing advanced MRI techniques, CDM® enables clinicians to predict, detect, and track changes in brain health with unprecedented accuracy. This capability not only aids in the diagnosis of various neurodegenerative diseases but also supports more efficient drug development by optimizing patient selection and trial performance.

The company’s commitment to enhancing patient care is evident in its efforts to provide personalized insights that help clinicians make informed decisions. CDM® has been recognized by the FDA with Breakthrough Device designation, underscoring its potential to transform the landscape of neurodegenerative disease management. By mapping differential patterns of brain changes and accurately tracking the progression of conditions, Oxford Brain Diagnostics aims to improve communication between healthcare providers and patients, ultimately fostering a proactive approach to brain health. Their research and collaborations further emphasize the importance of understanding brain microstructure in developing targeted therapies and improving outcomes for patients suffering from these debilitating conditions.

United Kingdom

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company's patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer's and other neurodegenerative diseases.

Oxford Brain Diagnostics Ltd

Company Details